vs
Side-by-side financial comparison of Allstate (ALL) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
PERRIGO Co plc is the larger business by last-quarter revenue ($1.1B vs $922.0M, roughly 1.2× Allstate). Allstate runs the higher net margin — 266.6% vs -127.8%, a 394.4% gap on every dollar of revenue. On growth, Allstate posted the faster year-over-year revenue change (7.2% vs -2.5%). Over the past eight quarters, PERRIGO Co plc's revenue compounded faster (1.3% CAGR vs -75.8%).
The Allstate Corporation, together with its subsidiaries, provides property and casualty, and other insurance products in the United States and Canada. The company operates through Allstate Protection; Protection Services; Allstate Health and Benefits; and Run-off Property-Liability segments. The Allstate Protection segment offers private passenger auto and homeowners insurance; specialty auto products, including motorcycle, trailer, motor home, and off-road vehicle insurance; other personal ...
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
ALL vs PRGO — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $922.0M | $1.1B |
| Net Profit | $2.5B | $-1.4B |
| Gross Margin | — | 32.6% |
| Operating Margin | -1400.3% | -116.0% |
| Net Margin | 266.6% | -127.8% |
| Revenue YoY | 7.2% | -2.5% |
| Net Profit YoY | — | -3093.9% |
| EPS (diluted) | $9.25 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $922.0M | — | ||
| Q4 25 | $17.3B | $1.1B | ||
| Q3 25 | $17.3B | $1.0B | ||
| Q2 25 | $16.6B | $1.1B | ||
| Q1 25 | $16.5B | $1.0B | ||
| Q4 24 | $16.5B | $1.1B | ||
| Q3 24 | $16.6B | $1.1B | ||
| Q2 24 | $15.7B | $1.1B |
| Q1 26 | $2.5B | — | ||
| Q4 25 | $3.8B | $-1.4B | ||
| Q3 25 | $3.7B | $7.5M | ||
| Q2 25 | $2.1B | $-8.4M | ||
| Q1 25 | $595.0M | $-6.4M | ||
| Q4 24 | $1.9B | $-44.4M | ||
| Q3 24 | $1.2B | $-21.0M | ||
| Q2 24 | $331.0M | $-108.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 32.6% | ||
| Q3 25 | — | 36.1% | ||
| Q2 25 | — | 34.4% | ||
| Q1 25 | — | 37.6% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | — | 37.2% | ||
| Q2 24 | — | 37.0% |
| Q1 26 | -1400.3% | — | ||
| Q4 25 | — | -116.0% | ||
| Q3 25 | — | 7.0% | ||
| Q2 25 | — | 4.3% | ||
| Q1 25 | — | 4.5% | ||
| Q4 24 | — | 10.0% | ||
| Q3 24 | — | 7.4% | ||
| Q2 24 | — | -2.5% |
| Q1 26 | 266.6% | — | ||
| Q4 25 | 22.1% | -127.8% | ||
| Q3 25 | 21.7% | 0.7% | ||
| Q2 25 | 12.7% | -0.8% | ||
| Q1 25 | 3.6% | -0.6% | ||
| Q4 24 | 11.7% | -3.9% | ||
| Q3 24 | 7.2% | -1.9% | ||
| Q2 24 | 2.1% | -10.2% |
| Q1 26 | $9.25 | — | ||
| Q4 25 | $14.24 | $-10.23 | ||
| Q3 25 | $13.95 | $0.05 | ||
| Q2 25 | $7.76 | $-0.06 | ||
| Q1 25 | $2.11 | $-0.05 | ||
| Q4 24 | $7.07 | $-0.32 | ||
| Q3 24 | $4.33 | $-0.15 | ||
| Q2 24 | $1.13 | $-0.79 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $31.6B | $2.9B |
| Total Assets | $124.0B | $8.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $4.9B | — | ||
| Q3 25 | $8.7B | $432.1M | ||
| Q2 25 | $9.6B | $454.2M | ||
| Q1 25 | $6.5B | $409.9M | ||
| Q4 24 | $4.5B | $558.8M | ||
| Q3 24 | $7.0B | $1.5B | ||
| Q2 24 | $5.3B | $542.8M |
| Q1 26 | — | — | ||
| Q4 25 | $7.5B | — | ||
| Q3 25 | $8.1B | — | ||
| Q2 25 | $8.1B | — | ||
| Q1 25 | $8.1B | — | ||
| Q4 24 | $8.1B | — | ||
| Q3 24 | $8.1B | — | ||
| Q2 24 | $8.1B | — |
| Q1 26 | $31.6B | — | ||
| Q4 25 | $30.6B | $2.9B | ||
| Q3 25 | $27.5B | $4.4B | ||
| Q2 25 | $24.0B | $4.5B | ||
| Q1 25 | $22.1B | $4.4B | ||
| Q4 24 | $21.4B | $4.3B | ||
| Q3 24 | $20.9B | $4.6B | ||
| Q2 24 | $18.6B | $4.5B |
| Q1 26 | $124.0B | — | ||
| Q4 25 | $119.8B | $8.5B | ||
| Q3 25 | $120.4B | $10.1B | ||
| Q2 25 | $115.9B | $10.1B | ||
| Q1 25 | $115.2B | $9.8B | ||
| Q4 24 | $111.6B | $9.6B | ||
| Q3 24 | $113.7B | $11.2B | ||
| Q2 24 | $108.4B | $10.4B |
| Q1 26 | — | — | ||
| Q4 25 | 0.24× | — | ||
| Q3 25 | 0.29× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.37× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.39× | — | ||
| Q2 24 | 0.43× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $175.4M |
| Free Cash FlowOCF − Capex | — | $148.6M |
| FCF MarginFCF / Revenue | — | 13.4% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.0B | $175.4M | ||
| Q3 25 | $3.3B | $51.7M | ||
| Q2 25 | $1.9B | $75.9M | ||
| Q1 25 | $2.0B | $-64.5M | ||
| Q4 24 | $1.7B | $312.6M | ||
| Q3 24 | $3.2B | $42.2M | ||
| Q2 24 | $2.4B | $9.5M |
| Q1 26 | — | — | ||
| Q4 25 | $2.9B | $148.6M | ||
| Q3 25 | $3.2B | $29.8M | ||
| Q2 25 | $1.9B | $56.7M | ||
| Q1 25 | $1.9B | $-90.0M | ||
| Q4 24 | $1.7B | $274.9M | ||
| Q3 24 | $3.1B | $15.1M | ||
| Q2 24 | $2.3B | $-18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 16.7% | 13.4% | ||
| Q3 25 | 18.8% | 2.9% | ||
| Q2 25 | 11.3% | 5.4% | ||
| Q1 25 | 11.4% | -8.6% | ||
| Q4 24 | 10.0% | 24.2% | ||
| Q3 24 | 18.9% | 1.4% | ||
| Q2 24 | 14.7% | -1.8% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 2.4% | ||
| Q3 25 | 0.3% | 2.1% | ||
| Q2 25 | 0.0% | 1.8% | ||
| Q1 25 | 0.6% | 2.4% | ||
| Q4 24 | 0.3% | 3.3% | ||
| Q3 24 | 0.4% | 2.5% | ||
| Q2 24 | 0.4% | 2.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.78× | — | ||
| Q3 25 | 0.88× | 6.89× | ||
| Q2 25 | 0.89× | — | ||
| Q1 25 | 3.30× | — | ||
| Q4 24 | 0.88× | — | ||
| Q3 24 | 2.69× | — | ||
| Q2 24 | 7.13× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALL
Segment breakdown not available.
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
